Objective: This review describes ongoing efforts to develop a medical therapy to limit abdominal aortic aneurysm (AAA) growth.
Abdominal aortic aneurysm (AAA) is an important cause of premature death worldwide. Recent estimates suggest an annual death rate due to aortic aneurysm of 2.8/100,000 (>20 million), representing a 12% increase in the last 20 years. 1 Although the highest death rates per year are reported in the developed regions of Australasia (8.38/100,000) and Western Europe (7.68/100,000), rapid increases in mortality rates are being reported in underdeveloped nations. 1 In the United States and parts of Western Europe, death rates resulting from ruptured AAA have fallen by >50% over the same time period, coinciding with dramatic reductions in per capita cigarette consumption, increased elective surgical repair of AAA, and improved management of cardiovascular disease risk factors. [2] [3] [4] [5] [6] [7] The estimated death rate each year due to AAA in North America is 6.11/100,000. 1 The management of AAA is guided mainly by aneurysm size and sometimes by the rate of aortic diameter enlargement during subsequent periodic surveillance imaging. 8 Small AAAs (<55 mm in diameter) are usually managed conservatively and monitored by regular imaging surveillance. Most small AAAs continue to enlarge after diagnosis and eventually undergo surgical repair. 9, 10 Large AAAs ($55 mm) are usually managed by endovascular exclusion or open surgical repair. Currently, no medical treatments have proven effective in limiting AAA growth. This review provides an update of research being undertaken to identify nonsurgical methods of reducing the rate of AAA growth, including insights into some of the challenges experienced in this research, a discussion of outcome measures that maybe used within these studies, and current investigations to test novel treatments to limit AAA growth.
CURRENT THEORIES REGARDING AAA PATHOGENESIS
Studies investigating mechanisms of AAA pathogenesis have used animal models, aortic tissues, blood samples, and epidemiologic data. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Findings from these studies are detailed in a number of prior reviews and, therefore, are not discussed in detail here. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Advanced age, smoking, male sex, family history of AAA, and history of hypertension or atherosclerosis-associated events are all established risk factors for AAA. 22 Examination of human AAA biopsy specimens and studies in rodent models of AAA suggest that inflammation, extracellular matrix remodelling, oxidative stress, vascular smooth muscle cell dysfunction, angiogenesis, and thrombosis are all important in AAA pathogenesis (Table I ).
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Human studies with large cohorts have reported the association of a number of inherited genetic mutations with AAA, such as single nucleotide polymorphisms on chromosome 9p21.3, within intron 1 of DAB2 interacting protein (DAB2IP), and within intron 2 of the gene encoding low-density lipoprotein receptor-related protein 1 (LRP1). 17 Mice with targeted inactivation of LRP1 within vascular smooth muscle cells are prone to aortic aneurysm formation, suggesting this gene may play a protective role against AAA. 17 The reported increased risk for AAA associated with these risk alleles is, however, only w1.1-fold to 1.2-fold, perhaps limiting the translational potential of these observations.
Recent studies have highlighted the potential role of epigenetic regulation in the pathogenesis of AAA. MicroRNAs (miRNAs) are nonprotein-coding RNA sequences that can modulate the transcription of coding segments of DNA. The expression of a number of different miRNAs (such as miR-29b and miR-155) within the aorta or circulating blood has been associated with AAA diagnosis in small studies. 13, 21 Modulating the expression of some miRNAs has been shown to promote or inhibit the development of AAA within rodent models. 13, 21 For example, antagonizing miR-29b has been reported to limit aortic expansion in the angiotensin II-, elastase-and fibrillin 1-deficient mouse models by limiting aortic inflammation and extracellular matrix remodelling. 13, 21 Experimental studies have suggested the potential efficacy of a number of strategies for limiting AAA growth, including inhibiting mast cells, blocking matrix metalloproteinases, inhibiting angiogenesis, antagonizing platelet aggression, and inhibiting angiotensin II, as previously reviewed. 15, 18 Translating insights derived during rodent experiments into effective treatments for small AAAs has proven challenging, however. The relevance of findings from rodent AAA studies to human AAA remains controversial. 23 Human AAA tissue is principally available after surgical repair of advanced disease. Analysis of such samples may have limited relevance to pathogenic processes prevalent earlier in the course of the disease, when medical therapies are most likely to be effective. Inflammation, for example, is considered central to AAA pathogenesis based on findings from human biopsy specimens from end-stage AAA and rodent models; however, rapid expansion and rupture of a previously small AAA has occurred in at least one patient receiving immunosuppression after a kidney transplant. 15, 18, 24 Ultimately, clinical trials are required to examine the potential efficacy of any drug or strategy thought to be effective in limiting AAA growth.
DESIGNING TRIALS TO TEST NEW TREATMENTS FOR SMALL AAA
The remainder of this review focuses on the designs and findings of clinical trials that have examined the efficacy of treatments to slow AAA growth. Designing and performing such trials presents a number of challenges, including those common to most clinical trials such as obtaining adequate recruitment and retention of patients and ensuring patient compliance and consistency of data reporting. Some of the unique challenges to designing small AAA trials are summarized in Table II and considered in more detail in another review. 25 These challenges include the slow rate of AAA growth in most patients, meaning that accurate outcome assessments are very important; the frequent loss of patients to AAA repair during follow-up, which limits the ability to study AAA growth for extended periods; and the frequency of multiple comorbidities in AAA patients that limits the range of interventions for which these patients are suitable. Together, these and other considerations increase the difficulty of designing effective clinical trials to identify treatments to slow AAA growth.
Outcome measures in current clinical trials of medical therapies for AAA One of the main considerations in any clinical trial is the most appropriate outcome assessment. The aim of any AAA treatment is the prevention of aneurysm-related death; however, this is not a practical outcome measure in small AAA trial because aneurysms that expand to >55 mm are usually repaired. Listed below are other outcome measures currently in use or of potential value in small AAA trials based on imaging the AAA or analyzing circulating blood samples. These have recently been reviewed in some detail elsewhere. 26 AAA diameter. In clinical practice, maximum AAA diameter is the preferred surrogate measure for disease progression. Diameter is an established predictor of rupture risk and, hence, is used to guide intervention. 8 However, considerable intraobserver and interobserver variation exists in the assessment of diameter. 25 Variation can occur at a number of stages during the assessment of maximum AAA diameter, including the identification of the site of maximum diameter, the orientation in which the diameter is measured (eg, sagittal or coronal), whether diameter is measured perpendicular to the plane of blood flow (ie, orthogonal) or within any axial plane, and whether the wall is included in the diameter measurements (Table II) . A clearly established AAA diameter measurement protocol, with demonstrated reproducibility, is essential for any AAA trial. Ultrasound imaging, computed tomography (CT), and magnetic resonance imaging (MRI) are possible methods for measuring AAA diameter. Ultrasound imaging is the most commonly used, cheapest, and least invasive. Ultrasound imaging also provides the most potential for observer error, although many groups have previously reported acceptable reproducibility. CT involves radiation exposure, although recent equipment uses smaller doses of X-rays than previous machines. CT-derived images, like those from MRI, lend themselves more readily to central or core laboratory review enabling more rigorous development of accurate assessment protocols. CT and MRI are, however, relatively expensive compared with ultrasound imaging. AAA volume. By using automated or semiautomated programs with CT and MRI, it is possible to estimate the total volume of the infrarenal aorta with good reproducibility. 27 Previous research suggests that AAA volume is a more sensitive marker of AAA progression than diameter and, therefore, potentially more applicable to the short-term follow-up inherent in clinical trials. 27 The relationships between AAA volume and AAA rupture or requirement for surgical repair are, however, not established. AAA volume does, however, correlate strongly with diameter, so the presence of these relationships would be expected. Biomechanical assessments. AAA rupture is believed to occur when the stress exerted on the aortic wall exceeds its strength. It has been suggested that estimates of wall stress and strength may be better predictors of AAA rupture risk than simple morphologic assessments such as diameter and volume. Finite element analysis has been used to estimate peak wall stress (PWS) and peak wall rupture index (PWRI). 28 A recent meta-analysis reported that PWS was significantly greater in 144 patients with ruptured or symptomatic AAAs than in 204 individuals with intact AAAs. 29 Whether PWS or PWRI are better at predicting AAA rupture than maximum AAA diameter is yet to be determined, and to date, neither measure has been adopted in clinical practice. Current methods of estimating PWS and PWRI require a number of assumptions, such as the thickness of the aortic wall, which limits their accuracy. Whether an adequately accurate and user-friendly system of measuring PWS can be developed for clinical use remains to be established. Functional imaging. Functional imaging seeks to obtain information about the severity of the aortic wall pathology. Positron emission tomography (PET) combined with CT (PET/CT) imaging has been used to image AAAs, and increased 18-fluorodeoxyglucose (18-FDG) uptake has been reported in symptomatic AAAs. 30 However other studies have reported no 18-FDG uptake in AAAs, and the value of PET/CT as an outcome measure for AAA drug trials remains uncertain. 31 Other functional imaging modalities, such as MRI assessment of phagocytic activity of macrophages using superparamagnetic iron oxide as a contrast agent, are being studied but remain insufficiently validated for use as end points in clinical trials.
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Circulating markers of AAA progression. A large number of circulating markers of AAA growth have been previously reported, 26, 34 but in most cases, the original association of these markers with AAA growth has not been replicated in subsequent confirmatory studies. The ability of the biomarkers to predict AAA growth independent of initial maximum AAA diameter is also uncertain. Two markers related to thrombus remodelling, namely plasma D-dimer and plasminantiplasmin complex, were associated with AAA growth, after adjusting for initial AAA diameter, in at least two independent studies. [35] [36] [37] Whether changes in such circulating markers in response to a drug therapy will be reflected in favorable effects on AAA progression is currently unknown; therefore, the value of using such markers as outcome measures in small AAA trials is unknown.
CURRENT AND RECENT STUDIES INVESTIGATING THE EFFICACY OF TREATMENTS TO SLOW AAA GROWTH
A large number of drug targets for AAA have been suggested based on work in preclinical models or human association studies, as previously reviewed. 38 However, relatively few drugs have been examined in well-designed randomized trials to date, although a number of such investigations are ongoing. Tables III  and IV summarize recent and ongoing randomized trials examining drug treatments to limit AAA growth. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Some of these studies are discussed in more detail below.
b-Blockers. b-Blockers lower blood pressure and have been suggested to correct excessive extracellular matrix remodelling. 38 b-Blockers are routinely provided to patients with Marfan syndrome to retard aortic root dilatation, although their ability to do so remains controversial. 50 The b-blocker propranolol was reported to have no significant effect in limiting AAA growth in three clinical trials, with all reporting poor patient compliance with treatment (Table III) . [39] [40] [41] In the largest of these trials, 42% of patients were unable to continue the assigned propranolol dosage of 80 mg/day. 39 An ongoing study is comparing the efficacy of the b-blocker atenolol and the angiotensin-receptor blocker valsartan in limiting AAA growth (Table IV) . 48 Doxycycline. Doxycycline is probably the most investigated drug in preclinical models of AAA. These studies have consistently reported that doxycycline inhibits AAA development. Promising results of using doxycycline to limit AAA growth were also reported in pilot human trials. 38 In rodent studies and pilot human trials, doxycycline has been reported to limit extracellular matrix remodelling and inflammation. 38 Doxycycline has particularly been suggested to reduce matrix metalloproteinase activity. 38 Therefore, the recent report of a 286 patient double-blind, placebo-controlled, randomized trial, the Pharmaceutical Aneurysm Stabilisation Trial Study (PHAST), assessing the efficacy of doxycycline (100 mg daily) in limiting AAA growth, was eagerly awaited. 42 Patients underwent an aortic ultrasound study every 6 months for 18 months by a single blinded physician using a mobile ultrasound device. The largest AAA diameter was measured from the inner wall to the inner wall of the aorta in the anterior-posterior orthogonal plane. The investigators reported an intraobserver repeatability coefficient of 1.6 mm.
The study was stopped at the time of a planned interim analysis because the stopping rule for futility was met. At this stage, at least 12 months of followup was available for all patients. Patients allocated doxycycline experienced a significantly larger increase in AAA diameter over 18 months than those receiving placebo, although the difference was small (difference in diameter increase was 0.8 mm; 95% confidence interval, 0.1-1.4 mm; P ¼ .016) and reported to be of no clinical significance. Doxycycline administration did not influence the requirement for elective AAA repair (16.1% for those receiving doxycycline and 16.5% for those allocated placebo; P ¼ .83). Only 11 patients (7.6%) allocated doxycycline and three receiving placebo (2.1%) left the study because of drug-related adverse effects; however, compliance was not reported. An additional trial is underway in the United States examining the efficacy of a higher dose of doxycycline (100 mg twice daily) in a planned sample of 248 patients (Table IV) . 49 Mast cell inhibition. Mast cells have been identified within human AAA biopsy specimens, and animal studies have suggested a role for mast cell inhibition in limiting AAA development. 15, 51 The Anti-inflammatory
Oral Treatment of AAA (AORTA) trial examined the efficacy of three doses of the mast cell inhibitor pemirolast (10, 25 and 40 mg/d) in slowing AAA growth over 12 months in 326 patients. 43 Outcome was assessed using electrocardiogram-gated ultrasound-acquired videos of the aorta analyzed centrally by two blinded readers. Maximum AAA diameter was assessed from readings performed using two methods of measuring diameter. The first method measured from the leading edge of the adventitia in the anterior wall to the leading edge of the adventitia in the posterior wall. The second method measured from the leading edge of the adventitia in the anterior wall to the luminal intimal border in the posterior wall. The limits of agreement of the measurements (reproducibility) was stated to be w3 mm. AAA growth rates were similar in patients receiving placebo and different doses of pemirolast (P ¼ .556; Table III ). Circulating levels of tryptase, a mast cell product, were not significantly different among the groups, raising questions regarding the efficacy of pemirolast in reducing aortic mast cell activity.
Angiotensin II. A large amount of preclinical data implicates angiotensin II in AAA formation and rupture. 15, 16, 18, 52 Angiotensin II promotes inflammation and matrix remodelling and raises blood pressure. 15, 16, 18, 52 The most commonly used AAA model relies on a subcutaneous angiotensin II infusion to create experimental aneurysms. 52 Human association studies have reported conflicting results on the association between angiotensin-converting enzyme (ACE) inhibitor prescription and the outcomes of AAA. 38 A large population study reported that individuals prescribed ACE inhibitors were less likely to present with a ruptured AAA. 53 In contrast, a report from the United Kingdom Small AAA trial reported faster AAA growth in patients receiving ACE inhibitors. 54 Other small AAA surveillance series have reported no association between ACE inhibitor prescription and AAA growth. 38 Bicknell et al 44 very recently reported the results of a 224-person randomized placebo-controlled trial that examined the efficacy of the ACE inhibitor perindopril (10 mg/d) in limiting AAA growth. The trial also included patients allocated the calcium channel blocker amlodipine (5 mg/d). Patients were assessed by repeat ultrasound imaging for up to 2 years. Perindopril (mean reduction, 9.5 mm Hg) and amlodipine (mean reduction, 6.7 mm Hg) were reported to effectively lower systolic blood pressure. However neither treatment was reported to affect AAA growth (Table III) . 44 Two current randomized trials are examining the efficacy of angiotensinreceptor blockers in limiting AAA growth (Table IV) . 45, 48 Evidence from these trials should, hopefully, clarify the value of inhibiting angiotensin II in limiting AAA growth.
Antiplatelet treatments. Most AAAs contain a large volume of intraluminal thrombus, and the volume of this thrombus has been correlated to AAA growth. 55 AAA thrombus contains high numbers of inflammatory cells and elevated concentrations of matrix-degrading enzymes and cytokines, all of which have been implicated in AAA pathogenesis. 15, 22 In some animal models, antiplatelet agents have been shown to inhibit AAA Immunosuppression has been suggested to promote AAA progression in at least one documented case 24 An overwhelming body of evidence implicates inflammation and matrix remodelling in AAA pathogenesis [15] [16] [17] [18] [19] [20] [21] [22] Inappropriate dose or agent An intermediate dose of doxycycline was chosen in PHAST. 42 No significant reduction of tryptase concentration was found in AORTA 42 The dose of doxycycline chosen in PHAST was based on a pilot study 64 AAA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme.
development and rupture. 56 A current clinical trial is examining the efficacy of the antiplatelet agent ticagrelor in limiting AAA growth (Table IV) . 46 Cyclosporine A. Previous animal studies suggest that transforming growth factor-b1 (TGF-b1) inhibits AAA development, most likely through promoting aortic fibrosis and modifying inflammation. 57 Dai et al 58 reported that a short course of the immunesuppressant cyclosporine A upregulated TGF-b1 and limited AAA formation in two rodent models. The effect of cyclosporine A was abrogated by the coadministration of an antibody blocking TGF-b1. The efficacy of a short course of cyclosporine A to limit AAA growth is currently being examined in an ongoing human trial (Table IV) . 47 Cell-based immunomodulatory studies. Accumulating evidence suggests that autoimmunity contributes to the pathogenesis of AAA. Key to this concept are two phenomena well characterized in AAA patients: activation of the adaptive immune system with clonal expansion of T-cell follicles in aortic tissue 59, 60 and decreased number and immune suppressor function of regulatory cells permitting the generation of autoimmune responses against self-antigens within the aorta. 
CONCLUSIONS AND FUTURE DIRECTIONS
The last decade has seen an explosion of preclinical studies focused on identifying treatment targets to limit AAA growth. This is now being followed by a small wave of human clinical trials. The initial reports of these trials, however, have all been negative. The negative findings of the PHAST, AORTA, and Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK (AARDVARK) trials have raised a number of concerns regarding the validity of the current approaches used to develop effective medications for AAA. Some examples of these concerns are listed in Table V . [15] [16] [17] [18] [19] [20] [21] [22] 24, 42, 63, 64 Doxycycline, in particular, had been proven effective in multiple animal models of AAA and pilot human studies, which are outcomes at odds with the findings of the PHAST trial. 42 Why promising preclinical and pilot human studies have not translated into effective therapies remains to be determined. The Non-invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA [3] CT) doubles the daily doxycycline dose, which may prove more effective. Current investigations are focused on identifying and testing novel AAA agents as well as best practices for outcome assessment and meaningful surrogate end points. Considerable enthusiasm remains for further investigations in this area, driven by emerging AAA science as well as the compelling clinical need in many older patients ill suited to surgical repair. Efforts to standardize outcomes are and will be essential in driving the field forward. 
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